Liu Sean Shih-Yao, Opperman Lynne A, Buschang Peter H
Department of Orthodontics and Oral Facial Genetics, School of Dentistry, Indiana University, Indianapolis, IN 46202, USA.
Am J Orthod Dentofacial Orthop. 2009 Dec;136(6):768.e1-8; discussion 768-9. doi: 10.1016/j.ajodo.2009.03.035.
The goal of this study was to evaluate whether human recombinant bone morphogenetic protein-2 (rhBMP-2) enhances sutural bone formation or causes premature sutural fusion.
Thirty 6-week-old rabbits underwent midsagittal sutural expansion. The animals were randomly assigned to receive 0 (control), 0.1 mg per milliliter, or 0.4 mg per milliliter of rhBMP-2, delivered by an absorbable collagen sponge placed over the suture. A 100-g constant force was delivered for 33 days by using a nickel-titanium spring to expand the suture between 2 miniscrew implants anchored in the frontal bone. At days 10, 20, and 30, sutural separation was evaluated and modeled over time as polynomials by using multilevel statistical procedures. Bone formation and sutural gaps were analyzed histomorphometrically between days 10 and 20 and days 20 and 30.
The control group showed significantly greater overall sutural bone formation than did the 2 rhBMP-2 groups. Over time, bone formation decreased significantly in all groups. Between days 10 and 20, the 0.4 mg per milliliter group produced significantly more (58%) bone than did the 0.1 mg per milliliter group; there were no significant differences in bone formation between the 2 experimental groups between days 20 and 30. Both 0.1 and 0.4 mg per milliliter of rhBMP-2 in the absorbable collagen sponge caused premature fusion by forming a bony bridge connecting the ectocranial aspect of the sutural margins. Premature fusion significantly reduced sutural separation between 10 and 30 days (to 56% and 62% of control values for the 0.1 and 0.4 mg per milliliter groups, respectively). There were no significant differences in sutural separation between the 0.1 and 0.4 mg per milliliter groups.
Compared with the 0.1 mg per milliliter group, 0.4 mg per milliliter of rhBMP-2 accelerated sutural bone formation between days 10 and 20. After 10 to 20 days, rhBMP-2 in the absorbable collagen sponge caused premature sutural fusion, despite the constant expansion forces.
本研究的目的是评估重组人骨形态发生蛋白-2(rhBMP-2)是否能促进缝合骨形成或导致过早的缝合融合。
30只6周龄的兔子接受矢状缝扩张。将动物随机分为3组,分别接受0(对照组)、0.1毫克/毫升或0.4毫克/毫升的rhBMP-2,通过置于缝线上的可吸收胶原海绵给药。使用镍钛弹簧施加100克恒定力33天,以扩张固定在前额骨上的2个微型螺钉植入物之间的缝线。在第10、20和30天,评估缝合分离情况,并使用多级统计程序将其随时间建模为多项式。在第10至20天以及第20至30天之间,对骨形成和缝合间隙进行组织形态计量学分析。
对照组的缝合骨总体形成明显多于2个rhBMP-2组。随着时间的推移,所有组的骨形成均显著减少。在第10至20天之间,0.4毫克/毫升组的骨生成量比0.1毫克/毫升组显著多(多58%);在第20至30天之间,2个实验组的骨形成没有显著差异。可吸收胶原海绵中0.1毫克/毫升和0.4毫克/毫升的rhBMP-2均通过形成连接缝合边缘颅外侧面的骨桥导致过早融合。过早融合显著降低了10至30天之间的缝合分离(0.1毫克/毫升组和0.4毫克/毫升组分别降至对照组值的56%和62%)。0.1毫克/毫升组和0.4毫克/毫升组之间的缝合分离没有显著差异。
与0.1毫克/毫升组相比,0.4毫克/毫升的rhBMP-2在第10至20天之间加速了缝合骨形成。10至20天后,尽管有恒定的扩张力,可吸收胶原海绵中的rhBMP-2仍导致过早的缝合融合。